ChemoCentryx: A Lot Rides on the Approval of Avacopan
ChemoCentryx, Inc. (NASDAQ: CCXI) is a clinical-stage biopharmaceutical company that focuses on creating innovative therapeutics for treatment of autoimmune, inflammatory and oncology disorders with primary focus on orphan and rare diseases. The Company’s approach is centered on developing discrete chemokine or chemoattractant receptors that block...
